Aclaris Therapeutics to Provide Clinical Update on Key Biologic and Oral Inhibitor Programs on April 28, 2026
Aclaris Therapeutics will announce full results from the Phase 1a single and multiple ascending dose trial of its bispecific antibody ATI-052 tomorrow morning before the market opens. The company also plans to disclose the results of its lead indication selection process for its ITK/JAK3 Inhibitor ATI-2138.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.